Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| primate origin | 5676 | 2097104-58-8 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Spesolimab-sbzo is a humanized monoclonal immunoglobulin G1 antibody that inhibits interleukin-36 (IL-36) signaling by specifically binding to the IL36R. Binding of spesolimab-sbzo to IL36R prevents the subsequent activation of IL36R by cognate ligands (IL-36 alpha, beta and gamma) and downstream activation of pro inflammatory and pro-fibrotic pathways. The precise mechanism linking reduced IL36R activity and the treatment of flares of GPP is unclear.
|
| Dose | Unit | Route |
|---|---|---|
| 0.90 | g | P |
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 1, 2022 | FDA | BOEHRINGER INGELHEIM PHARMACEUTICALS INC | |
| Dec. 9, 2022 | EMA | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | |
| Sept. 26, 2022 | PMDA | NIPPON BOEHRINGER INGELHEIM CO., LTD. |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | L04AC22 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors |
| MeSH PA | D003879 | Dermatologic Agents |
| FDA EPC | N0000194039 | Interleukin-36 Receptor Antagonist |
| FDA MoA | N0000194040 | Interleukin-36 Receptor Antagonists |
| CHEBI has role | CHEBI:50748 | antipsoriatic |
| CHEBI has role | CHEBI:67079 | anti-inflammatory agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Pustular psoriasis | indication | 200973000 | |
| Erythrodermic psoriasis | indication | 200977004 | |
| Generalized pustular psoriasis | indication | 238612002 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Interleukin-1 receptor-like 2 | Membrane receptor | ANTAGONIST | Kd | 9.65 | DRUG LABEL | DRUG LABEL |
| ID | Source |
|---|---|
| CHEBI:757347 | CHEBI |
| CHEMBL4297911 | ChEMBL_ID |
| C000712973 | MESH_SUPPLEMENTAL_RECORD_UI |
| 12169 | IUPHAR_LIGAND_ID |
| DB15626 | DRUGBANK_ID |
| 1025551000122104 | SNOMEDCT_US |
| 4041692 | VANDF |
| 4041693 | VANDF |
| C5238146 | UMLSCUI |
| 10845 | INN_ID |
| D12066 | KEGG_DRUG |
| 361370 | MMSL |
| 40858 | MMSL |
| d09913 | MMSL |
| 019169 | NDDF |
| 5IB2J79MCX | UNII |
| 2610417 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0035 | INJECTION | 60 mg | INTRAVENOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0035 | INJECTION | 60 mg | INTRAVENOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0620 | INJECTION | 150 mg | INTRAVENOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-0620 | INJECTION | 150 mg | INTRAVENOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-7705 | INJECTION | 300 mg | INTRAVENOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0597-7705 | INJECTION | 300 mg | INTRAVENOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50222-360 | INJECTION | 60 mg | SUBCUTANEOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50222-361 | INJECTION | 150 mg | SUBCUTANEOUS | BLA | 30 sections |
| SPEVIGO | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50222-362 | INJECTION | 300 mg | SUBCUTANEOUS | BLA | 30 sections |